Zobrazeno 1 - 7
of 7
pro vyhledávání: '"R N Sherry Pierce"'
Autor:
Zeev Estrov, Danielle Hammond, R N Sherry Pierce, Courtney D. DiNardo, Tapan M. Kadia, Jorge Ramos-Perez, Koji Sasaki, Veronica A Guerra, Naveen Pemmaraju, Guillermo Garcia-Manero, Sanam Loghavi, Joseph D. Khoury, Paul Shilpa, Guillermo Montalban-Bravo, Farhad Ravandi, Marina Konopleva, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Naval Daver, Keyur P. Patel, Elias Jabbour, Koichi Takahashi, Gautam Borthakur, Kiran Naqvi
Publikováno v:
Blood. 136:26-29
INTRODUCTION: The current WHO definition requires presence of persistent absolute monocytosis for the diagnosis of chronic myelomonocytic leukemia (CMML). Oligomonocytic CMML (O-CMML), defined by presence of clinical and pathological features of CMML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734f4a2c83a46fddc19932e5020ac1ee
https://doi.org/10.1182/blood-2020-137212
https://doi.org/10.1182/blood-2020-137212
Autor:
Francis J. Giles, Kerim Kaban, Jorge Cortes, Moshe Talpaz, Hagop Kantarjian, Susan O'Brien, R N Sherry Pierce, Maher Albitar
Publikováno v:
Cancer. 88:570-576
BACKGROUND Chronic myelogenous leukemia (CML) represents a paradigm of the stepwise increment in disease aggressiveness, resistance to therapy, and transformation. Thrombopoietin (TPO) and its receptor, c-mpl, support the proliferation of multiple ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3035e221b5922a5c516d30415a36c910
https://doi.org/10.1002/(sici)1097-0142(20000201)88:3<570::aid-cncr12>3.0.co
https://doi.org/10.1002/(sici)1097-0142(20000201)88:3<570::aid-cncr12>3.0.co
Autor:
Guillermo Garcia-Manero, R N Sherry Pierce, Jorge E. Cortes, Srdan Verstovsek, Susan O'Brien, Jerome Zeldis, Francis J. Giles, Maher Albitar, Michael J. Keating, Hagop Kantarjian, Deborah A. Thomas, Stefan Faderl
Publikováno v:
Cancer. 106(9)
BACKGROUND Thalidomide is a putative antiangiogenesis agent with activity in several hematologic malignancies. METHODS Forty-four patients who had myelofibrosis with myeloid metaplasia received treatment with thalidomide in a Phase II clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc09ba6771683f6b22905913464950e
https://pubmed.ncbi.nlm.nih.gov/16583431
https://pubmed.ncbi.nlm.nih.gov/16583431
Autor:
William Wierda, Jianqin Shan, R N Sherry Pierce, Francis Giles, Jorge Cortes, Susan O'Brien, Elihu Estey, Guillermo Garcia-Manero, Stefan Faderl, Hagop Kantarjian, Elias Jabbour
Publikováno v:
Cancer. 106(5)
BACKGROUND Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML-type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and onc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fba3ca17661d0d653be8a28480f291c3
https://pubmed.ncbi.nlm.nih.gov/16435386
https://pubmed.ncbi.nlm.nih.gov/16435386
Autor:
Susan O'Brien, Hagop Kantarjian, Jianqin Shan, Jorge Cortes, William Plunkett, R N Sherry Pierce, Michael Keating, Miloslav Beran, Francis Giles, Elihu Estey
Publikováno v:
Cancer. 106(5)
BACKGROUND Progressive or higher-risk myelodysplastic syndrome (MDS) is often treated with intensive chemotherapy regimens used for acute myelogenous leukemia (AML). Patients with MDS are often older and may have contraindications to anthracycline-ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bbdb3ffe4448d1e246c1fb96508ded8
https://pubmed.ncbi.nlm.nih.gov/16435387
https://pubmed.ncbi.nlm.nih.gov/16435387
Autor:
Hagop Kantarjian, Jorge Cortes, Francis Giles, Michael Keating, Guillermo Garcia-Manero, Carlos Bueso-Ramos, Jianqin Shan, Srdan Verstovsek, R N Sherry Pierce, Susan O'Brien
Publikováno v:
Cancer. 104(3)
Although the prognosis is poor for patients with acute myelogenous leukemia (AML) who have disease recurrence after frontline therapy, this is a general reflection of first salvage therapies. The outcome of patients undergoing second salvage therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f01887792ecb53df1954bbb65f561d90
https://pubmed.ncbi.nlm.nih.gov/15973664
https://pubmed.ncbi.nlm.nih.gov/15973664
Autor:
Hagop Kantarjian, Susan O'Brien, A R N Sherry Pierce, Deborah A. Thomas, Mary Ann Weiser, Tony P. Lam
Publikováno v:
Cancer. 94(2)
BACKGROUND Although the safety and efficacy of granulocyte–colony-stimulating factor (G-CSF) (filgrastim) in the treatment of hematologic malignancies has been well established, to the authors' knowledge the optimal timing of filgrastim administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f73d82a63aa74fb16fbbf6f1beb5f32
https://pubmed.ncbi.nlm.nih.gov/11900213
https://pubmed.ncbi.nlm.nih.gov/11900213